Date: 2014-01-29
Type of information:
phase:
Announcement: intiation of the trial
Company: Cancer Research UK (UK)
Product: antibody treatment DI-B4
Action mechanism:
Disease: B-cell lymphoma
Therapeutic area: Cancer - Oncology
Country: UK
Trial details:
Latest
news: * On January 29, 2014, Cancer Research UK’s Drug Development Office (DDO) has launched a new clinical trial to treat lymphoma patients using the body’s own immune system to attack cancerous B-cells growing out of control. This is an early phase trial to test how 40 patients will deal with this new antibody treatment DI-B4, which targets a marker of both B-cells and the cells that will grow up to be B-cells. The trial will be led from Southampton General Hospital, with other centres including The Christie hospital in Manchester, the Royal Liverpool University Hospital and the Oxford University Hospital. It will last four and a half years with an 18 month follow up. These centres are part of Cancer Research UK’s network of Experimental Cancer Medicine Centres (ECMCs) which bring together cancer doctors and scientists to speed up the flow of ideas from the lab bench to a patient’s bedside.
